English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes Serum troponin is the best biomarker for the diagnosis of acute coronary syndrome, but it takes considerable time before a definitive diagnosis is available. The purpose of this study was to evaluate whether a multimarker approach, using the biochip cardiac array, would facilitate the early diagnosis. Serum biomarkers were determined on admission (≤6 hrs) and after 6 hours in 42 patients suspected for ACS. Cardiac troponin I was measured by a sensitive assay (STATcTnI) and cardiac markers (H-FABP, myoglobin, cTnI, CK-MB mass, carbonic anhydrase III) were assayed with the use of Biochip Array Technology. STATcTnI concentrations, within the first 6 hours, were elevated >99th percentile for the reference population in 83.3% of subjects, but none reached the cut-off for AMI. On admission H-FABP was the only marker with 90.5% sensitivity in all ACS cases and 100% sensitivity in STEMI/NSTEMI patients. The sensitivity of myoglobin at presentation was 71.4% in ACS, however, combined sensitivity of myoglobin and H-FABP reached 95.2%. Lowering the cut-off for cTnI allowed early diagnosis (≤6 hrs) in only 26.2% of ACS patients and 95.2% after the next 6 hours. In unstable angina the cardiac panel was not sufficiently accurate for early risk stratification. In conclusion, testing for both markers, H-FABP and sensitive cardiac troponin, available with the cardiac array may facilitate the early detection of myocardial injury in clinical practice. Upotreba Tehnologije Biočipa za Rano Dijagnostikovanje Akutnih Koronarnih Sindroma Troponin u serumu je najbolji biomarker za dijagnostikovanje akutnog koronarnog sindroma, ali do postavljanja definitivne dijagnoze prolazi dosta vremena. Cilj studije je da se ispita da li pristup s više markera, pomoću biočip metode omogućava rano dijgnostikovanje. Biomarkeri u serumu određeni su prilikom prijema (≤6 časova) i posle 6 časova kod 42 pacijenata sa simptomima akutnog koronarnog sindroma. Srčani troponin I izmeren je osetljivim testom (STATcTnI) dok su srčani markeri (H-FABP, mioglobin, cTnI, maseni CK-MB, karbo-anhidraza III) određeni pomoću tehnologije »Biochip Array«. Koncentracije dobijene pomoću STATcTnI u prvih 6 časova bile su povišene >99 procenata u odnosu na referentnu populaciju kod 83,3% ispitanika, ali ni kod koga nisu prešle »cut-off« vrednost za akutni infarkt miokarda. Prilikom prijema samo je marker H-FABP imao senzitivnost od 90,5% u svim slučajevima akutnih koronarnih sindroma i senzitivnost od 100% kod pacijenata sa STEMI/NSTEMI. Osetljivost mioglobina na prijemu bila je 71,4% za AKS, međutim, osetljivost kombinacije mioglobina i H-FABP dostigla je 95,2%. Snižavanje »cut-off« vrednosti za cTnI omogućilo je rano dijagnostikovanje (≤6 časova) kod samo 26,2% pacijenata sa AKS i 95,2% posle sledećih 6 časova. Kod nestabilne angine srčani panel nije bio dovoljno precizan za ranu stratifikaciju rizika. Može se zaključiti da testiranje oba markera - H-FABP i senzitivnog srčanog troponina dostupno putem metode »Cardiac Array« - može olakšati ranu detekciju oštećenja miokarda u kliničkoj praksi.